Reported Earlier, ImmunityBio Has Received FDA Approval For ANKTIVA, A First-In-Class IL-15 Receptor Agonist, For BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.